Immunomedics (IMMU) Misses Q2 EPS by 50c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Immunomedics Reports Results For Period Ended December 31, 2018, Strengthens Board And Announces Senior Leadership Changes
February 25, 2019 4:01 PM ESTPreparation for Resubmission of BLA for Sacituzumab Govitecan Continuing
Phase 2 Data in mTNBC Published in New England Journal of Medicine
Oral Presentation of Updated Phase 1/2 Results with Sacituzumab Govitecan in Metastatic Urothelial Cancer at the 2019 Genitourinary Cancers Symposium
MORRIS PLAINS, N.J., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Â Immunomedics, Inc., (NASDAQ:... More
